Archive for NCT05162755

A Phase 1a/1b, Open-label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Anti-neoplastic Activity of S095029 (Anti-NKG2A) as Monotherapy and in Combination with Sym021 (Anti-PD-1) in Patients with Advanced Solid Tumor Malignancies followed by an Expansion Part with Triplet Combinations of S095029 and Sym021 and an anti-HER2 mAb or anti-EGFR mAbs (futuximab/modotuximab) in Patients with Metastatic Gastric or Colorectal cancers